SOURCE: BioCentury Publications, Inc.

BioCentury Publications, Inc.

March 20, 2015 13:09 ET

BioCentury Hosts the 22nd Annual Future Leaders in the Biotech Industry

Featuring Rising Private Plays & Momentum-Building Public Companies With Upcoming Milestones and Over 120 Unpartnered Assets

REDWOOD CITY, CA and NEW YORK, NY--(Marketwired - Mar 20, 2015) -  BioCentury will convene the 22nd Annual Future Leaders in the Biotech Industry in New York City on Friday, March 20th at 8 a.m. at the Millennium Broadway Hotel & Conference Center.

The event showcases a full slate of 60 biopharma companies hand-picked on the basis of investor validation, upcoming milestones, unpartnered assets and innovative science, informed by BioCentury's business intelligence platform.

Over 700 life science investment professionals and pharmaceutical business development and licensing executives have pre-registered for the event. Walk-up registration is available starting at 7:15 a.m. on Friday, March 20th on the 4th floor of the Millennium Broadway Conference Center, 133 West 44th Street.

The Future Leaders Class of 2015 is doing its part to keep the biotech bull market running. The 24 public and 22 private companies have raised $5.5 billion in capital, including $2.6 billion since the beginning of 2014.

Public companies at Future Leaders are collectively up 21% this year, easily outdistancing the 0.4% decline in the Dow Jones Industrial Average and 0.3% gain in the S&P 500. Over that same period, the aggregate market cap of the Future Leaders public companies has grown by $3.1 billion, from $14.8 billion to $17.9 billion.

This year's conference also features a Next Wave track of 14 early stage, privately held companies, allowing attendees to bone up on the up-and-coming platform plays and development stage companies advancing their assets to the clinic.

The Class of 2015 also features select IPO stories and public companies nearing key Phase II and III milestones in addition to international companies approaching value inflection points. Disease areas covered by the Class of 2015 include cancer, infectious disease, hematology, and neurological and autoimmune disorders. This year we also feature a track of companies with special regulatory designations from FDA and other regulatory authorities that should help speed their products to market.

The Class of 2015 companies comprise a solid mix of innovative science and platform assets and provide ample partnering opportunities.

These Future Leaders companies possess more than 120 unpartnered products, including 25 products in Phase II development, 20 products in Phase I and 78 products in preclinical development.

"As we shift into the later phases of the bull market, it becomes more of a 'stock pickers' market," said BioCentury Publisher Eric Pierce. "The Future Leaders Class of 2015 is aiming to show how they can create more value for investors going forward."

The 2015 Presenting Companies

Presenting companies were screened by BioCentury's industry analysts using BioCentury's BCIQ online business intelligence platform. The result is an independently selected mix of companies with proven fundraising capacity, the prospect for key partnerships and proximity to potentially transformational milestones.

Presenting Companies

Acceleron Pharma Inc. (XLRN)
Actinium Pharmaceuticals Inc. (ATNM)
Advaxis Inc. (ADXS)
Aerie Pharmaceuticals Inc. (AERI)
Alnylam Pharmaceuticals Inc. (ALNY)
Ardelyx Inc. (ARDX)
Argos Therapeutics Inc. (ARGS)
AuraSense Therapeutics LLC
Avelas Biosciences Inc.
Cara Therapeutics Inc. (CARA)
Celator Pharmaceuticals Inc. (CPXX)
Cleave Biosciences Inc.
Cortendo AB
CymaBay Therapeutics Inc. (CBAY)
Deciphera Pharmaceuticals LLC
Dimension Therapeutics Inc.
Effector Therapeutics Inc.
Enumeral Biomedical Holdings Inc. (ENUM)
Esperion Therapeutics Inc. (ESPR)
Forward Pharma A/S (FWP)
GeNeuro S.A.
Global Blood Therapeutics Inc.
Helomics Corp.
Kadmon Corp. LLC
Kolltan Pharmaceuticals Inc.
Kymab Ltd.
Marinus Pharmaceuticals Inc. (MRNS)
Medgenics Inc. (MDGN) (not found in BCIQ)
Metabolic Solutions Development Co.
Naurex Inc.
NeoStem Inc. (NBS)
Opsona Therapeutics Ltd.
Paratek Pharmaceuticals Inc. (PRTK)
Protagonist Therapeutics Inc.
Relmada Therapeutics Inc. (RLMD)
RestorGenex Corp. (RESX)
Savara Pharmaceuticals
Syndax Pharmaceuticals Inc.
Syros Pharmaceuticals Inc.
Taris Biomedical Inc.
Trevena Inc. (TRVN)
uniQure N.V. (QURE)
VBL Therapeutics Ltd. (VBLT)
Voyager Therapeutics Inc.
Xencor Inc. (XNCR)

Next Wave Companies

Aridis Pharmaceuticals LLC
ArmaGen Inc.
Atterocor Inc.
Blaze Bioscience Inc.
Coferon Inc.
Enterome Bioscience S.A.
G1 Therapeutics Inc.
Kineta Inc.
ONL Therapeutics Inc.
Raze Therapeutics Inc.
Scholar Rock LLC
Second Genome Inc.
TomegaVax Inc.
Vaxin Inc.

See the Presenting Company schedule at

Top Sponsors Demonstrate Long-Term Commitment to Industry

The prestigious group of 2015 sponsors is anchored by Gold Sponsors Johnson & Johnson Innovation and WBB Securities LLC; Silver Sponsors Abbvie, Laidlaw & Company, Tiberend Strategic Advisors, Inc. and The Trout Group; joined by and luncheon sponsor Panasonic Healthcare.

This premier Wall Street event is one of two annual U.S. investor conferences organized by BioCentury. The next Wall Street conference, the 22nd Annual NewsMakers in the Biotech Industry, will take place in New York City on September 10, 2015, at the Millennium Broadway Hotel & Conference Center.

BioCentury also co-organizes BioEquity Europe, which will take place in Vienna, May 19 - 20, 2015. The 16th Annual BioEquity Europe will be the premier event for financial dealmakers looking for investor-validated life science companies positioning themselves to attract capital, and for business development and licensing professionals from pharmaceutical companies to assess top partnering and licensing prospects.

About BioCentury

Since 1993, BioCentury Publications, Inc. has provided essential biopharma industry intelligence to a global audience of biotech and pharmaceutical executives, investors, regulators, public policy makers and the scientific community. This audience has benefited from BioCentury's deep knowledge, data-driven analysis, independent perspective and trustworthy content available through the company's publications, data products and collaborative industry conferences in the U.S., Europe and Asia.

BioCentury's titles include the flagship BioCentury®; its translational science journal BioCentury Innovations; and its BioCentury Extra™ online daily newspaper. These timely journals are backed by BCIQ: BioCentury Online Intelligence™, an online business intelligence resource.

For more information, visit